Page 29 - NON-INVASIVE TESTS FOR EVALUATION OF LIVER DISEASE SEVERITY AND PROGNOSIS
P. 29
Clinical Practice Guidelines cohort of HCV-infected individuals with and without HIV infection. Am J
Gastroenterol 2010;105:1346–1353.
[329] Colecchia A, Colli A, Casazza G, Mandolesi D, Schiumerini R, Reggiani LB, [332] Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, et al.
et al. Spleen stiffness measurement can predict clinical complications in Predicting clinical and histologic outcomes based on standard laboratory
compensated HCV-related cirrhosis: a prospective study. J Hepatol tests in advanced chronic hepatitis C. Gastroenterology 2010;138:136–146.
2014;60:1158–1164. [333] Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D,
Goodman ZD, et al. Serum fibrosis markers are associated with liver
[330] Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, disease progression in non-responder patients with chronic hepatitis C. Gut
et al. A prospective analysis of the prognostic value of biomarkers 2010;59:1401–1409.
(FibroTest) in patients with chronic hepatitis C. Clin Chem 2006;52:
1887–1896.
[331] Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, et al. Noninvasive
markers of liver fibrosis are highly predictive of liver-related death in a
28 Journal of Hepatology 2015 vol. xxx j xxx–xxx
Please cite this article in press as: EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J
Hepatol (2015), http://dx.doi.org/10.1016/j.jhep.2015.04.006
Gastroenterol 2010;105:1346–1353.
[329] Colecchia A, Colli A, Casazza G, Mandolesi D, Schiumerini R, Reggiani LB, [332] Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, et al.
et al. Spleen stiffness measurement can predict clinical complications in Predicting clinical and histologic outcomes based on standard laboratory
compensated HCV-related cirrhosis: a prospective study. J Hepatol tests in advanced chronic hepatitis C. Gastroenterology 2010;138:136–146.
2014;60:1158–1164. [333] Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D,
Goodman ZD, et al. Serum fibrosis markers are associated with liver
[330] Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, disease progression in non-responder patients with chronic hepatitis C. Gut
et al. A prospective analysis of the prognostic value of biomarkers 2010;59:1401–1409.
(FibroTest) in patients with chronic hepatitis C. Clin Chem 2006;52:
1887–1896.
[331] Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, et al. Noninvasive
markers of liver fibrosis are highly predictive of liver-related death in a
28 Journal of Hepatology 2015 vol. xxx j xxx–xxx
Please cite this article in press as: EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J
Hepatol (2015), http://dx.doi.org/10.1016/j.jhep.2015.04.006
